Episode Details

Back to Episodes
Disease-modifying glaucoma drugs

Disease-modifying glaucoma drugs

Published 5 months, 3 weeks ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/disease-modifying-glaucoma-drugs

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Introduction Glaucoma is a chronic eye disease where nerve cells in the retina and optic nerve gradually die, often causing blindness if untreated. For decades, the main proven treatment has been lowering intraocular pressure (IOP) – the fluid pressure inside the eye – to slow damage (). This is done with eye drops, laser or surgery. But pressure isn’t the whole story. Many patients still lose vision even when their pressure is well-controlled. In fact, about one-third of treated patients eventually go blind in one eye (). And some people (so-called “normal-tension” glaucoma) get damage even with normal pressure. These facts tell us that simply draining fluid is not enough. Glaucoma is fundamentally a neurodegenerative disease – nerves are dying. Scientists are now exploring whether new drugs can modify the disease itself rather than just treating pressure, by protecting the nerves and improving the eye’s blood supply. In this article, we’ll explain what “disease-modifying” means in glaucoma and why it’s exciting. We’ll look at the importance of ocular blood flow and the endothelin pathway (which can choke blood vessels), and how improving blood flow or cell health might save vision. We’ll also cover PER-001, a new drug in development by Perfuse Therapeutics (now owned by Bayer), which targets endothelin. We’ll weigh the evidence – what’s been shown so far in small trials, what’s still uncertain – and discuss what the future might hold in 3–10 years. The tone is hopeful but realistic: disease-modifying therapies could change how we treat glaucoma, but they are not cures (at least not yet). What “Disease-Modifying” Means in Glaucoma A disease-modifying therapy is one that changes the course of the disease itself, instead of just relieving symptoms. In glaucoma, that would mean a drug that actually slows or stops the nerve-cell death in the eye, not just reduces pressure. It’s a bit like how some arthritis drugs do more than just mask pain by slowing joint damage. For glaucoma, the idea is often called “neuroprotection” – protecting the retinal ganglion cells (RGCs), the neurons that carry vision signals from the eye to the brain. A classic definition says neuroprotection is treating glaucoma “by a mechanism independent of lowering IOP” (). Right now, no therapy has been proven to do this in patients. In large, decades-long studies only pressure lowering showed a clear benefit. In fact, a 2023 review in Molecular Aspects of Medicine notes that “current strategies only target intraocular pressure… and do not directly target the neurodegenerative processes” of glaucoma (). It adds that up to 40% of patients still progress to blindness in at least one eye despite strict pressure control (). So researchers say we urgently need therapies that go beyond pressure. In plain terms: imagine the optic nerve as a plant that not only needs the right water pressure but also good soil and light. Pressure drops help water travel (good!), but if the root cells are sick or starved, the plant will still die. Disease-modifying treatments aim to brighten the light or improve the soil – directly helping the cells survive and function. Blood Flow and Endothelin: Why They Matter One big area of research is improving ocular blood flow. The retina is one of the body’s hungriest tissues for oxygen and nutrients. It’s like a high-performance engine needing constant fuel. If blood

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us